首页> 外文期刊>European Journal of Pharmacology: An International Journal >Torasemide, a long-acting loop diuretic, reduces the progression of myocarditis to dilated cardiomyopathy.
【24h】

Torasemide, a long-acting loop diuretic, reduces the progression of myocarditis to dilated cardiomyopathy.

机译:长效loop利尿剂Torasemide可减少心肌炎向扩张型心肌病的进展。

获取原文
获取原文并翻译 | 示例
           

摘要

Torasemide is a long-acting loop diuretic that combines the effects of both furosemide and spironolactone. It has been reported that torasemide may block the renin-angiotensin-aldosterone system and therefore it might attenuate myocardial remodeling accompanied by left ventricular dysfunction. However, nothing is known about the effect of torasemide on myocardial remodeling in a rat model in which myosin-induced experimental autoimmune myocarditis might develop into dilated cardiomyopathy. Experimental autoimmune myocarditis was elicited in Lewis rats by immunization with porcine cardiac myosin. Twenty-eight days after immunization, we investigated the effects of torasemide on metabolic and neurohumoral parameters, cardiac fibrosis and remodeling in experimental autoimmune myocarditis rats. Diuresis was increased dose-dependently by torasemide; the urinary potassium and sodium excretion was significantly decreased and increased, respectively. Myocardial functional parameters measured by hemodynamic andechocardiographic studies were significantly improved by torasemide treatment in a dose-dependent manner. The area of fibrosis, myocyte size and the myocardial protein levels of transforming growth factor-beta1, collagen III, and aldosterone synthase were significantly decreased, and the sarcoplasmic reticulum Ca2+ ATPase2 protein level was significantly increased by torasemide treatment. Moreover, the plasma levels of angiotensin II and aldosterone were increased and atrial natriuretic peptide was decreased in a dose-dependent manner. Our results indicate that torasemide treatment significantly improved left ventricular function and ameliorated the progression of cardiac remodeling beyond its renal effects in rats with chronic heart failure after experimental autoimmune myocarditis.
机译:托拉塞米是一种长效loop利尿剂,结合了速尿和螺内酯的作用。据报道,妥拉塞米可能会阻断肾素-血管紧张素-醛固酮系统,因此可能减弱伴随左心功能不全的心肌重塑。但是,关于妥拉塞米对大鼠模型心肌重塑的影响,目前尚不清楚,在大鼠模型中,肌球蛋白诱导的实验性自身免疫性心肌炎可能发展为扩张型心肌病。通过用猪心脏肌球蛋白免疫在Lewis大鼠中引发实验性自身免疫性心肌炎。免疫后第二十八天,我们研究了妥拉塞米对实验性自身免疫性心肌炎大鼠代谢和神经体液参数,心脏纤维化和重塑的影响。托拉塞米剂量依赖性地增加利尿作用;尿中钾和钠的排泄分别显着减少和增加。托拉塞米治疗以剂量依赖性方式显着改善了血流动力学和超声心动图研究测得的心肌功能参数。通过妥拉塞米治疗,纤维化面积,心肌细胞大小以及转化生长因子-β1,胶原蛋白III和醛固酮合酶的心肌蛋白水平显着降低,肌浆网Ca2 + ATPase2蛋白水平显着提高。而且,血管紧张素II和醛固酮的血浆水平以剂量依赖性方式增加,而心钠素减少。我们的结果表明,在实验性自身免疫性心肌炎后,患有慢性心力衰竭的大鼠,妥拉塞米治疗可显着改善左心室功能,并改善心脏重塑的进程,超出其肾功能。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号